Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer

International Journal of Cancer

Volumn 125, Issue 11, 2009, Pages 2687-2696

  Udler, Miriam S ^a,b   Azzato, Elizabeth M ^a,c   Healey, Catherine S ^a   Ahmed, Shahana ^a   Pooley, Karen A ^a   Greenberg, David ^d   Shah, Mitul ^a   Teschendorff, Andrew E ^e,f   Caldas, Carlos ^e   Dunning, Alison M ^a   Ostrander, Elaine A ^b   Caporaso, Neil E ^c   Easton, Douglas ^a   Pharoah, Paul D ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Eastern Cancer Registration and Information Centre   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Breast cancer; Genetic epidemiology; Polymorphism; Survival

Indexed keywords

AROMATASE; CATECHOL METHYLTRANSFERASE; ESTROGEN RECEPTOR ALPHA; ESTROGEN SULFOTRANSFERASE; PROGESTERONE RECEPTOR; STERYL SULFATASE; CARRIER PROTEIN; CYTOCHROME P450 1A1; ESR1 PROTEIN, HUMAN; ESTRONE SULFOTRANSFERASE; MRFAP1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; STS 1 PROTEIN, HUMAN; STS-1 PROTEIN, HUMAN; SULFOTRANSFERASE; TUMOR PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID METABOLISM; BREAST TUMOR; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GENETICS; LUNG CARCINOMA; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARRIER PROTEINS; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 CYP1A1; ESTROGEN RECEPTOR ALPHA; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SULFOTRANSFERASES; SURVIVAL RATE;

EID: 70350702803     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24678     Document Type: Article

References (38)

1. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-978
2. Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 2000;74:357-364 (Pubitemid 32126247)
3. Lange CA. Challenges to defining a role for progesterone in breast cancer. Steroids 2008;73:914-921
4. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-433
5. Subramanian A, Salhab M, Mokbel K. Oestrogen producing enzymes and mammary carcinogenesis: a review. Breast Cancer Res Treat 2008;111:191-202.
6. Choi JY, Lee KM, Park SK, Noh DY, Ahn SH, Chung HW, Han W, Kim JS, Shin SG, Jang IJ, Yoo KY, Hirvonen A, et al. Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1090-1095 (Pubitemid 40656452)
7. Long JR, Cai Q, Shu XO, Cai H, Gao YT, Zheng W. Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival. Pharmacogenet Genomics 2007;17:331-338 (Pubitemid 46608540)
8. Long JR, Kataoka N, Shu XO, Wen W, Gao YT, Cai Q, Zheng W. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol Biomarkers Prev 2006;15:2115-2122 (Pubitemid 44877034)
9. Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, Easton DF, Pharoah PP. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 2002;62:3052-7.
10. Einarsdottir K, Darabi H, Li Y, Low YL, Li YQ, Bonnard C, Sjolander A, Czene K, Wedren S, Liu ET, Hall P, Humphreys K, et al. ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res 2008;10:R15.
11. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 2006;38:209-213 (Pubitemid 43177235)
12. Sobin LH, Wittekind C. TNM classification of malignant tumors, 5th edn. New York: Wiley-Liss, 1997.
13. The International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437:1299-1320.
14. Livingston RJ, von Niederhausern A, Jegga AG, Crawford DC, Carlson CS, Rieder MJ, Gowrisankar S, Aronow BJ, Weiss RB, Nickerson DA. Pattern of sequence variation across 213 environmental response genes. Genome Res 2004;14:1821-1831 (Pubitemid 39386496)
15. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217-1223
16. Pooley KA, Healey CS, Smith PL, Pharoah PD, Thompson D, Tee L, West J, Jordan C, Easton DF, Ponder BA, Dunning AM. Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol Biomarkers Prev 2006;15:675-682
17. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Pike MC. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36. (Pubitemid 36928743)
18. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, Easton DF, Day NE, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-945 (Pubitemid 38868140)
19. Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E, Boeing H, Buring J, et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 2007;67:1893-1897
20. Cai H, Shu XO, Egan KM, Cai Q, Long JR, Gao YT, Zheng W. Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women. Pharmacogenet Genomics 2008;18:657-664
21. Klein JP, Moeschberger M. Survival analysis: techniques for censored and truncated data, 2nd edn. New York: Springer, 2003.
22. Azzato EM, Greenberg D, Shah M, Blows F, Driver KE, Caporaso NE, Pharoah PDP. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer 2009;100:1806-1811
23. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin S-F, Dunning M, Barbosa-Morais NL, Green AR, Ellis IO, Tavare S, Caldas C, Miska EA. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007;8:R214.
24. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-541
25. Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, Chew KL, Dairkee SH, Jensen RM, Waldman FM. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003;63:7167-7175 (Pubitemid 37413454)
26. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005;102:13550-13555 (Pubitemid 41420886)
27. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-272
28. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536
29. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
30. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-679 (Pubitemid 40260888)
31. Teschendorff AE, Naderi A, Barbosa-Morais NL, Pinder SE, Ellis IO, Aparicio S, Brenton JD, Caldas C. A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol 2006;7:R101. (Pubitemid 46442938)
32. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1-27.
33. Ji Y, Olson J, Zhang J, Hildebrandt M, Wang L, Ingle J, Fredericksen Z, Sellers T, Miller W, Dixon JM, Brauch H, Eichelbaum M, et al. Breast cancer risk reduction and membrane-bound catechol-O-methyltransferase genetic polymorphisms. Cancer Res 2008;68:5997-6005.
34. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243-250 (Pubitemid 26226317)
35. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF. Catechol-O- methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001;61:6716-6722 (Pubitemid 32896493)
36. Goodman JE, Jensen LT, He P, Yager JD. Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics 2002;12:517-528 (Pubitemid 35177081)
37. Hirata H, Hinoda Y, Okayama N, Suehiro Y, Kawamoto K, Kikuno N, Rabban JT, Chen LM, Dahiya R. COMT polymorphisms affecting protein expression are risk factors for endometrial cancer. Mol Carcinog 2008;47:768-774
38. Matsui A, Ikeda T, Enomoto K, Nakashima H, Omae K, Watanabe M, Hibi T, Kitajima M. Progression of human breast cancers to the metastatic state is linked to genotypes of catechol-O-methyltransferase. Cancer Lett 2000;150:23-31.